Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna
- PMID: 2879626
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna
Abstract
We monitored acute tubular damage in 16 patients who received a 5-day course of ifosfamide (1.6 g/m2/day) and mesna (1.2 g/m2/day) therapy. Urinary concentrations of alanine aminopeptidase, N-acetyl-beta-D-glucosaminidase, and total protein increased in every patient, but the extent of tubular toxicity varied widely among patients. Evidence of toxicity was greatest in patients whose tumors involved the kidneys. The time course of enzymuria and proteinuria indicated tubular cell necrosis. We observed this acute toxic effect despite the administration of sufficient mesna to prevent hemorrhagic cystitis. Urinary marker concentrations returned towards pre-dose levels, and there were no increases in serum creatinine concentrations measured 3 weeks after treatment.
Similar articles
-
Mesna excretion and ifosfamide nephrotoxicity in children.Cancer Res. 1989 Dec 15;49(24 Pt 1):7153-7. Cancer Res. 1989. PMID: 2510931
-
Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.Cancer Chemother Pharmacol. 1989;25(1):70-2. doi: 10.1007/BF00694342. Cancer Chemother Pharmacol. 1989. PMID: 2574077
-
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.Cancer Res. 1987 Mar 1;47(5):1457-60. Cancer Res. 1987. PMID: 3815347
-
Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children.Pediatr Infect Dis J. 1989 May;8(5):278-82. Pediatr Infect Dis J. 1989. PMID: 2657616 Review.
-
Ifosfamide, mesna, and nephrotoxicity in children.J Clin Oncol. 1993 Jan;11(1):173-90. doi: 10.1200/JCO.1993.11.1.173. J Clin Oncol. 1993. PMID: 8418231 Review.
Cited by
-
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.Drugs. 1991 Sep;42(3):428-67. doi: 10.2165/00003495-199142030-00006. Drugs. 1991. PMID: 1720382 Review.
-
Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.Cancer Chemother Pharmacol. 1991;28(6):455-60. doi: 10.1007/BF00685822. Cancer Chemother Pharmacol. 1991. PMID: 1934249
-
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.Invest New Drugs. 2000 Aug;18(3):281-9. doi: 10.1023/a:1006490226104. Invest New Drugs. 2000. PMID: 10958599 Clinical Trial.
-
Ifosfamide nephrotoxicity in paediatric cancer patients.Eur J Pediatr. 1994 Feb;153(2):90-4. doi: 10.1007/BF01959214. Eur J Pediatr. 1994. PMID: 8157032
-
A systematic review of selected musculoskeletal late effects in survivors of childhood cancer.Curr Pediatr Rev. 2014;10(4):249-62. doi: 10.2174/1573400510666141114223827. Curr Pediatr Rev. 2014. PMID: 25403639 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical